Abstract If the patient has antibody to low incidence antigen providing compatible blood for transfusion is not a problem. It is however necessary to identify such antibodies to assess their potential to cause hemolytic transfusion reaction and hemolytic disease of newborn. We identified anti C w in patient's serum while investigating the cause of incompatible cross match in a female thalassemia patient. Anti C w is an antibody against C w (Rh8) antigen, which is a low incidence antigen of Rh system. This case also prompted us to study frequency of C w antigen in our donor population as the frequency of C w antigens in our population is not reported. Frequency of C w antigens in north Indian donors was found to be 1.2 %.
Introduction
During compatibility testing if patient's serum is found incompatible with only one donor unit, the possible causes could be ABO incompatible/DAT positive/polyagglutinable donor red cells or antibody to low incidence antigen in patient's serum [1] . If the patient has antibody to low incidence antigen providing compatible blood for transfusion is not a problem. It is however necessary to identify such antibodies to assess their potential to cause hemolytic transfusion reaction (HTR) and hemolytic disease of newborn (HDN). Also in multitransfused patients these antibodies may complicate the identification of other clinically significant antibodies. It is also of academic interest to identify such antibodies and antigens as many of the new low incidence antigens are discovered in this manner.
We identified anti C w in patient's serum while investigating the cause of incompatible crossmatch in a female thalassemia patient. Anti C w is an antibody against C w (Rh8) antigen, which is a low incidence antigen of Rh system [2] . This case, also prompted us to study frequency of C w antigen in our donor population as the frequency of C w antigens in our population is not reported. We also reviewed literature with regards to its potential to cause HDN as the patient was a young female of child bearing age group.
Case Report with Results
Two units of packed red cells were crossmatched for B positive 18 years old female thalassemia major patient by AHG gel technique at our institution. One unit these was found incompatible (3?), however second unit was fully compatible. Cross match was compatible by saline technique at room temperature. Five another B? units crossmatched for the patient were also found to be compatible. Two units of compatible blood were issued for the patient and incompatible crossmatch was further worked up.
On further investigations incompatible blood donor unit red cells were found to be Direct antiglobulin test negative (AHG gel column agglutination test: Diamed GmbH, Cressier, Switzerland), B positive on repeat blood grouping (ABO compatible) and not agglutinated by sera of group AB donors (polyagglutination negative).
Results of antibody screening and antibody identification done on patient's serum using ID Diacell I-II-II and ID-Diapanel (Diamed GmbH, Cressier, Switzerland) by AHG gel technique are shown in Table 1 and 2. Anti C W was identified in the patient's serum. It also reacted with C w positive cells from another lot of ID-Diapanel prepared from different set of donors and donor red cells identified as C w positive at our center on typing of 163 donors for this study. Anti C w titer in patient's serum was found to be 16. As this is a rare antibody aliquots of plasma from all subsequent blood samples sent for pretransfusion testing were preserved frozen.
The incompatible donor unit was found to be C W antigen positive by commercially available anti C W anti sera (Diamed GmbH, Cressier, Switzerland). Aliquots from C W positive donor red cell unit were preserved using 40 % glycerol at -80°C. The donor of incompatible blood unit was from Eastern India, whereas our center is located in central India.
Patient's red cells were found to be negative for C W antigen. This patient has been regularly transfused since the age of 6 months and has received [300 transfusions so far mostly at other centers. She was registered at our center recently and had been found to be negative for red cell alloantibodies nine months ago on screening. In frequently transfused patients the red cell antigen phenotype may not represent the true phenotype of the patient due to presence of transfused donor red cells more so if the last transfusion has been within 2-3 weeks and molecular typing is confirmatory. However last transfusion in this patient had been 6 weeks ago. The Rh antigen phenotype of patient, incompatible unit and compatible unit was found to be CcDee, CcCWDee and CCDee respectively. To find C W antigen frequency in north Indian donor population we typed 163 donors for C W antigen using commercially available anti C w antisera from (Diamed GmbH, Cressier, Switzerland); two out of 163 (1.2 %) of these were found to be C w antigen positive.
Discussion
The anti C w identified in this case is most likely transfusion induced. Since in this case anti C w was detected in a female patient of child bearing age group it was necessary to evaluate the antibody's potential to cause HDN and advise accordingly although for transfusion purposes crossmatch compatible blood could have been be issued. This antibody may have been present in patient's serum earlier also but as she was never screened for alloantibodies it remained undetected. It is essential that alloantibody screening should be done at scheduled intervals in frequently Table 1 Results of testing patient's serum with reagent red cell panel for antibody screening transfused patients in the Institution's policy is to issue blood AHG compatible blood without antibody screening.
On literature search few case reports of mild to severe HDN caused by anti C w were found. Table 3 summarizes the findings of reported studies. Anti C w was first described in 1946 by Callender and race in a DCe/DCe multitransfused patient with systemic lupus erythematosus who had been transfused DCe/DCe C w ? red cells [2] . In 1947, Lawler and Loghem reported first anti C W associated HDN [3] . Since then there have been infrequent case reports on anti C w associated moderate to severe HDN requiring intervention as summarized in Table 3 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , demonstrating that pregnancies affected by anti C w merit closer scrutiny. Table 4 shows the C w antigen frequency in this study in comparison to that reported from other parts of world. As seen in Table 4 the frequency of C w antigen is reported to be 1-3 % in most of the populations with exception of Finns, Lapps and Latvians where the frequency is reported to be higher. The reported frequency of C w antigen among Caucasians and blacks is reported to be 2 and 1 % respectively [13] . It is more frequent in Latvians (7 %) and Finns (4 %) [14] .
In view of clinical significance of anti C w antibody the patient was provided an antibody card for reference. It was also decided to issue crossmatch compatible blood for further transfusions and monitor antibody titre. Since patient was of child bearing age group she and her parents were counseled regarding anti C w antibody's potential to cause HDN and HTR and their prevention.
In certain countries however, it is reported that a C w positive cell is typically not included in a set of screening cells and thus anti C w may be missed on antibody screening although C w positive cell is included on antibody identification panel from most manufacturers [19] .
Conclusion
We suggest that C w antigen positive antibody screening cells should be used for antibody screening in pregnant women as these antibodies may not be as infrequent as they are thought to be and can result in clinically significant HDN. Also if these antibodies are identified, titer in maternal serum and assessment of fetal well being should be done aggressively.
This case illustrates that work of a transfusion service does not end with providing compatible blood as work up of incompatible cross match led us to detection of antibody to low frequency antigen in the patient's serum and prompted us to study the antigen frequency in our region. This approach may have far reaching consequences for the patient and growth of science. 
